Would you pay $700 a night to sleep under the stars at this Colorado resort?A DOOMSDAY prepper has revealed how she’s feeding her family for less this Christmas – using almost expired items from her costly stockpile. Rowan MacKenzie is well-known for her expert advice in preparing for any disaster, including the end of the world. The 40-year-old began stocking up her cupboards 13 years ago and initially started with long-life essentials, such as beans and rice. Over the years, she’s moved on to learning how to preserve goods and says that most of her stockpile shouldn’t expire for at least another 25 years. Though, thanks to her “flawless” rotation system, there’s little-to-no wastage – most of which the family consumes as part of their Christmas dinner. “Usually the holidays are when I do a lot of my stock rotation,” the homemaker told What's The Jam. READ MORE ON DOOMSDAY PREPPERS “This means that any items I have that go with a holiday meal [that are due to expire] are used up. “And in turn, I make room for more items. “Most of the dried fruits, nuts, sauces and canned goods are from my stock. “But mostly, it’s just bits and pieces that are almost out of date.” Most read in The US Sun Rowan, from the US, has spent over $350,000 on her stock, as well as a hidden underground bunker that has been built into her basement. And thanks to this whopping spend, she’s able to cut back in other areas - especially when feeding the masses at Christmas. She said: “My whole family attends, there’s usually around 15 people that I feed each year. “I don’t have to spend much since most of everything I need is already in my stock. “Usually, I only spend $50 on food for the entire holiday.” Rowan recently revealed how “grateful” she was that Trump had been elected back into the White House. There is no better feeling than knowing you are ready for anything that could happen and having your family protected." His victory has meant that she, and many other preppers, are able to “take a break” from rushed stockpiling due to his “hero” attitude. But for now, she has a strong warning to everyone this holiday season. She added: “My biggest advice: don’t panic. “Breathe, make a list and execute. “There is no better feeling than knowing you are ready for anything that could happen and having your family protected. Read More on The US Sun “My friends and family think I’m crazy. “But when the time inevitably comes, they won’t be calling me crazy then.”VMT-01 by Perspective Therapeutics for Metastatic Melanoma: Likelihood of ApprovalWOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, celebrated the closing of its business combination with Atlantic Coastal Acquisition Corp II (“ACAB”), a special purpose acquisition company, with a Nasdaq bell ringing ceremony. Abpro also celebrated the consummation of a PIPE offering raising $7 million in gross proceeds and a $2.76 million convertible note financing with YA II PN, LTD (“Yorkville”) to cover expenses in connection with the closing of the business combination. As previously announced, Abpro also has entered into a Standby Equity Purchase Agreement with Yorkville (the “SEPA”) pursuant to which Abpro has the right, but not the obligation, to issue up to $50 million in shares of its common stock to Yorkville upon registration of such shares, provided that no balance is outstanding on any promissory note to Yorkville (currently $3 million dollars outstanding). Among other restrictions and conditions set forth in the SEPA, the number of shares Abpro may request may not exceed the average of the daily traded amount of its shares of common stock during the five consecutive trading days preceding such request, and shall not cause Yorkville’s ownership to exceed 4.99% of the then outstanding common stock of Abpro, and the maximum amount of shares issued under the SEPA cannot exceed 19.99% of the outstanding common stock of Abpro without prior shareholder approval. Upon registration of the shares subject to the SEPA, Abpro has the right to receive financing for an additional $2 million. As previously announced, Abpro also has entered into a forward purchase agreement for the sale of up to 500,000 shares of common stock. Abpro believes that the various financings should significantly improve Abpro’s financial flexibility as it advances the development of its pipeline of its next-generation antibody therapies. “Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat oncology and ophthalmology indications,” said Ian Chan, CEO and co-founder of Abpro. “The funds are expected to help accelerate the advancement of our pipeline to clinical trials. The financing will also provide the foundation for ongoing development of novel immunotherapies and next-generation antibody treatments in our pipeline with the aim of improving the lives of patients in need.” Abpro is advancing its pipeline of next-generation antibody therapies for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These next-generation antibodies are developed using Abpro's proprietary DiversImmune® platform, which creates antibody therapies against traditionally difficult targets. Abpro has partnered with Celltrion , a leading South Korean pharmaceutical company, in an exclusive global collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancers. Soo Young Lee, Senior Vice President and Head of the New Drug Division of Celltrion Inc. and a member of Abpro's Board of Directors, remarked, “Abpro’s ABP 102 drug candidate has shown preclinical data indicating the potential for better efficacy and less toxicity. We look forward to working closely with Abpro to advance ABP 102 into clinical trials.” Tony Eisenberg, who serves as a Director of Abpro, and had served as Chief Strategy Officer of ACAB prior to the business combination, added, “It’s an honor to be part of Abpro and the groundbreaking work they are doing. The Atlantic Coastal team is excited to have successfully completed this business combination with Abpro and to work with the Abpro management team to execute their long-term operational and strategic objectives as they develop next-generation antibody therapies with the potential to save lives and generate real return for investors.” Abpro’s Chairperson, Miles Suk, stated, "As the chairperson of the board, I am honored to guide Abpro through this landmark achievement. This listing marks a new chapter of growth and opportunity, and we remain committed to delivering sustainable value to our shareholders." About Abpro Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro has partnered with Celltrion, which is a leading South Korean biotechnology company, ranked top 25 in the world by market capitalization, in an exclusive collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancer. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.com . Forward Looking Statements This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; Abpro’s ability to raise additional capital; the outcome of judicial proceedings to which Abpro or its subsidiaries is, or may become a party; failure to realize the anticipated benefits of the Business Combination, including difficulty in, or costs associated with, integrating the businesses of ACAB and Abpro; risks related to the rollout of Abpro’s business and the cost and timing of expected business milestones; the effects of competition on Abpro’s future business; and those factors discussed in Abpro’s public filings under the heading “Risk Factors,” and other documents of Abpro filed, or to be filed, with the SEC. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the “Risk Factors” section of Abpro’s public filings and other documents to be filed by Abpro from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward- looking statements, and while Abpro may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Abpro does not give any assurance that Abpro will achieve its expectations. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. Contacts Company: info@abpro.com Investors: ir@abpro.com Media: Jessica Yingling, Ph.D., Little Dog Communications Inc. jessica@litldog.com
Falcons drafting Penix no longer a head-scratcher with rookie QB shining in place of benched CousinsThe cryptocurrency market is a dynamic and ever-changing landscape, with Bitcoin often taking center stage. However, recent trends suggest a shift in power, with Bitcoin’s dominance waning and altcoins (alternative cryptocurrencies) poised for a potential surge. This phenomenon, known as “altseason,” occurs when altcoins outperform Bitcoin, often experiencing significant price increases. Is this the beginning of the next altseason? Let’s dive into the factors driving this shift and explore the potential implications for the crypto market. Bitcoin dominance, represented by the percentage of the total cryptocurrency market capitalization held by Bitcoin, has been on a declining trend. This decline indicates that investors are diversifying their portfolios and allocating more capital to altcoins. Several factors contribute to this trend, including the rise of decentralized finance (DeFi), the growing popularity of non-fungible tokens (NFTs), and the increasing institutional adoption of cryptocurrencies. These developments have fueled interest in altcoins with specific use cases and functionalities , leading to a more distributed market share. What is Bitcoin Dominance? Bitcoin dominance is a metric that measures the market capitalization of Bitcoin relative to the total market capitalization of all cryptocurrencies. It’s a key indicator of Bitcoin’s strength and influence within the crypto market. Why is Bitcoin Dominance Declining? Signs of an Approaching Altseason: Potential Implications for the Crypto Market: An altseason can bring significant opportunities for investors, with the potential for substantial gains in altcoin values. However, it’s crucial to remember that the crypto market is highly volatile, and investments carry inherent risks. Careful research, due diligence, and risk management are essential for navigating the altcoin market successfully. My Personal Experience: I’ve been involved in the crypto space since 2017, and I’ve witnessed firsthand the ebb and flow of Bitcoin dominance and altcoin cycles. During the 2017 bull run, altcoins experienced explosive growth, with some projects generating astronomical returns. However, I also learned the importance of thorough research and avoiding impulsive investment decisions. In the current market, I’m particularly excited about the potential of DeFi and NFTs, and I’m closely following the development of innovative altcoin projects in these areas. Navigating the Altcoin Market: The decline in Bitcoin dominance and the emergence of promising altcoin projects suggest that the next altseason may be on the horizon. This period could present exciting opportunities for crypto investors, but it’s crucial to approach the market with caution and a well-informed strategy. By staying informed, conducting thorough research, and managing risk effectively, investors can potentially capitalize on the opportunities that an altseason may bring.
Fiberglass Rebar Market 2024 Set for Major Growth Surge Over the Next DecadeOn a highly optimistic note, the major stock indexes soared as the markets opened today. The ChiNext Index, known as China's NASDAQ-style board of growth enterprises, led the way with an impressive 4.88% surge, underscoring the growing interest in innovative and high-growth companies. The A-share market as a whole also witnessed a substantial increase as investors displayed renewed confidence in the market outlook.